

---

## Jay M. Portnoy, MD

Division of Allergy, Immunology, Pulmonary and Sleep Medicine  
Section of Allergy/Immunology  
Medical Director of Telemedicine  
Children's Mercy Kansas City

### Education:

Allergy/Immunology Fellowship 1983-85  
University of Michigan School of Medicine  
Ann Arbor, MI 48109

Pediatric Resident 1980-83, The Children's Mercy Hospital  
Kansas City, Missouri 64108

Medical School 1976-80. Received MD May 1980  
University of Missouri-Columbia School of Medicine  
Columbia, Missouri 65212

Undergraduate 1974-76. Received BS, Magna Cum Laude 1976  
University of Michigan, Ann Arbor, Michigan 48109

California Institute of Technology 1972-74  
Pasadena, California.

### Licenses:

Missouri  
Kansas

### Board Certifications:

American Board of Allergy/Immunology - Oct. 1985, Recertified Oct. 1995.  
Currently participating in Maintenance of Certification (MOC)  
American Board of Pediatrics - Jan. 1985  
National Boards - 1981

### Academic Appointments:

Medical Director, Telemedicine, The Children's Mercy Hospital. 2016 – Present  
Director, Division of Allergy/Asthma/Immunology, The Children's Mercy Hospital. 1985-2017  
Professor of Pediatrics, University of Missouri-Kansas City School of Medicine. 1997-present.  
Director, University of Missouri-Kansas City Allergy Fellowship Training Program. 1997-2006  
Co-Director, Children's Mercy/Kansas U. Allergy/Immunology Fellowship Training Program 1985-97  
Director, Dept of Health Management. The Children's Mercy Hospital. 2004-2007.

### Organizations:

Fellow, American Academy of Pediatrics (AAP)  
Fellow, American College of Allergy, Asthma, and Immunology (ACAAI)  
Fellow, American Academy of Allergy, Asthma, and Immunology (AAAAI)  
Member, AOA

---

**Offices and Board of Directors:**

American Board of Allergy & Immunology (ABAI). 2014-2019. Vice-chair of MOC 2014-16, chair of MOC 2016- 2018  
 Allergy/Immunology Residency Review Committee (RRC). 2008-2015. Vice-chair 2014-15.  
 President, American College of Allergy, Asthma & Immunology. 2007-2008.  
 Vice President, American College of Allergy, Asthma & Immunology 2005-6.  
 Board of Directors, Black Healthcare Coalition. 2006-2009.  
 Board of Directors. American Lung Assn of Missouri. 2004-2006.  
 Board of Directors, American Lung Assn of Western Missouri. 1998-2003  
 Board of Directors. Asthma Camp Consortium. 1996-2001  
 Board of Regents, American College of Allergy, Asthma, and Immunology- 1994 to 1997  
 Board of Directors, Joint Council of Allergy and Immunology - 1991 to 1995  
 President, Missouri State Allergy Society – 1993-95  
 Board of Directors, Missouri State Allergy Society - 1989-91  
 President, Kansas City Allergy Society - 1988.

**Editorships and Editorial Boards**

Editorial Board, J Allergy Clin Immunol in Practice. 2020 to present.  
 Editorial Board, Current Allergy Practice. 1993 to present  
 Regional Editor, World Allergy Organization Journal. 2008 to 2012.  
 Section Editor, Annals of Allergy and Asthma. Appointed 2002 to 2005  
 Editor, Current Opinion on Allergy & Asthma. Issue on Pediatric Allergy. 2004 and 2005  
 Editor, Current Allergy and Asthma Reports. Issue on Pediatric Allergy. 2001-2013  
 Editorial Board, Allergy Watch. 1998-2001.  
 Editorial Board, Annals of Allergy and Asthma. 1994 to 2006

**Other Appointments**

FDA advisory panel (CBER) Vaccines and Related Biological Products Advisory Committee (VRBPAC). 2021-present  
 FDA advisory panel (CBER), Allergenic Extracts. 2017-2022  
 FDA advisory panel (CDER). Respiratory and allergy drugs. 2010-13  
 FDA advisory panel (CBER), Allergenic Extracts. 2005-2010  
 Special Emphasis Panel. T-cell Epitopes. NIAID. 2011.

**Committees:****American College of Allergy, Asthma & Immunology (ACAAI)**

Chair, COLA oversight committee. 2008-2014  
 Web Editor. 2009 – 2011  
 Chair, Allied Health Committee. 2004 – 2006  
 Co-Chair, Indoor Allergy Media Campaign. 2004, 2008-2009  
 Chair, Meet the professor breakfast committee. 2000-2006  
 Chair, Publications Committee- 1997-2001  
 Chair, Professional Education Committee. 1997-2001  
 Immunotherapy committee. 1998-present. Chair 2003-2006.  
 Joint Taskforce of Primary Care Rotations. 1996 – present. Co-Chair 1996-1998 and 2001 – 2005  
 Board review committee. 1998-present. Chair 2004.  
 Program Committee. 1997 and 2000-present  
 Public relations network. 1999-present.  
 Allied Health Professionals Committee. 2003 – 2006  
 Technology and computers committee. 1997-present.  
 Training Program Directors Committee, AAAAI and ACAAI. 1987-2005  
 Aerobiology Committee. 1998-present. Chair 2000 – 2002.  
 Finance committee. 1997-2001, 2005-2009  
 Chair, Inner City Asthma Committee- 1994-1997  
 CME Committee 1987-1991

---

### **American Academy of Allergy, Asthma & Immunology (AAAAI)**

Allied Health Committee. Co-chair 2023-present.  
EORD interest section. Secretary 2017-2018, Vice chair 2019-2020, Chair 2021-23.  
Co-Chair. Joint Telemedicine Taskforce (with the ACAAI) 2019-2022  
Indoor Air Committee. Chair, 2005-2006.  
Member, Aerobiology Committee. Chair, 2000-2002  
Residency Review Subcommittee. 2000-2005  
Information Technology Taskforce. 2000- 2005  
Ad Hoc committee for computerizing allergy training programs. 2000-2004  
Allergy and Immunology MKSAP, 3<sup>rd</sup> Edition author group. 2000-2002.  
Workshop Committee. 2000-2003.  
Executive committee of the Allergen Standardization Committee- 1994-2000  
Asthma camps committee- 1991-2001  
Environmental and Occupational Disorders Interest Section- Workshops committee representative 2000-2003  
Medical informatics committee- 1991-1997  
Quality of care for asthma committee- 1991-1997  
National Issues Committee. 1993-1996.

### **World Allergy Organization (WAO)**

Emerging Societies Committee- 2007 – 2009

### **Other committees**

Joint Taskforce on the Future of Allergy. Co-chair. 2008-2010  
Joint AAAAI/ACAAI Advocacy Working Group. ACAAI representative. 2004  
Joint Taskforce on Practice Parameters. 1998-present. Co-chair 2001 – 2017  
CPT committee, Joint Council of Allergy, Asthma & Immunology. 2000-2005  
Chair, National Allergy Bureau oversight committee. 2000-2002  
Executive committee of the Allergy/Immunology Section. Am Acad Pediatrics. 1995-1997.  
Training Program Directors Committee, AAAAI and ACAAI. 1987-2005  
Steering Committee. Aspen Allergy Conference. 1997-2006  
Asthma & Allergy Foundation Investigator Award Review Panel. 1997-2006.  
American Lung Association National Grant Review Panel. 1998-2004

### **Local committees**

Clinical Practice Guidelines (CPG) for anaphylaxis and CPG for asthma. 2020-2022  
Team leader, Department of Pediatrics Strategic Planning. 2013-15  
Chair, Clinical Practice Guidelines Taskforce. Children's Mercy Hospital. 2001-2006.  
Project director, Asthma disease management program. Children's Mercy Hospital. 2001-2006.  
Appointed to Quality Council. Children's Mercy Hospital. 2002-2008.  
Internet Steering Committee, Children's Mercy Hospital. 1995-2004.  
Chair, Asthma Disease Management Taskforce. Family Health Partners. 2000

### **Honors and Awards**

Gold Headed Cane Award. ACAAI. 2021 Annual Meeting.  
Phil and Barbara Lieberman and Friends Lectureship. AAAAI. 2020 virtual meeting.  
Elliott Ellis Lectureship. AAAAI. 2012.  
Educator of the Year Award. Children's Mercy Hospital. 2007.  
Making a Difference Award. AAN/MA. 2005  
National Leadership Award. Environmental Protection Agency (EPA). 2005  
Bela Schick Lectureship. ACAAI. 2004  
Distinguished Fellow Award. ACAAI. 2001  
Distinguished Service Award. ACAAI. 1999  
Pharmacia Allergy Research Foundation Fellowship. 1994  
Kraemer Research Award. Children's Mercy Hospital. 1993

**Publications:**

1. Pandya A, Waller M, Portnoy JM. How Can Artificial Intelligence Help With Management of Allergic Conditions? *J Allergy Clin Immunol Pract.* 2024;12(4):1017-8
2. Oppenheimer J, Bender B, Sousa-Pinto B, et al. Use of Technology to Improve Adherence in Allergy/Immunology. *J Allergy Clin Immunol Pract.* 2024 (in press)
3. Miller C, Manious M, Portnoy J. Artificial intelligence and machine learning for anaphylaxis algorithms. *Curr Opin Allergy Clin Immunol.* 2024;24(5):305-12
4. Pfaar O, Portnoy J, Nolte H, et al. Future Directions of Allergen Immunotherapy for Allergic Rhinitis: Experts' Perspective. *J Allergy Clin Immunol Pract.* 2024;12(1):32-44
5. Pandya A, Parashar S, Waller M, et al. Telemedicine beyond the pandemic: challenges in the pediatric immunology clinic. *Expert Rev Clin Immunol.* 2023;19(9):1063-73
6. Lugogo N, O'Connor M, George M, et al. Expert Consensus on SABA Use for Asthma Clinical Decision-Making: A Delphi Approach. *Curr Allergy Asthma Rep.* 2023;23(11):621-34
7. Hamid N, Portnoy JM, Pandya A. Computer-Assisted Clinical Diagnosis and Treatment *Curr Allergy Asthma Rep.* 2023 Sep;23(9):509-517. doi: 10.1007/s11882-023-01097-8. Epub 2023 Jun 23. PMID: 37351722 Review
8. Portnoy J, Shroba J, Tilles S, Romdhani H, Donelson SM, Latremouille-Viau D, Bungay R, Chen K, McCann W. Real-world experience of pediatric patients treated with peanut (*Arachis hypogaea*) allergen powder-dnfp. *Ann Allergy Asthma Immunol.* 2023 Feb 2:S1081-1206(23)00079-0. doi: 10.1016/j.anai.2023.01.027
9. Ciaccio C, Goldsobel AB, Anagnostou A, Beyer K, Casale TB, Deschildre A, Fernández-Rivas M, Hourihane JO, Krawiec M, Lieberman J, Scurlock AM, Vickery BP, Smith A, Tilles SA, Adelman DC, Brown KR; RAMSES (ARC007) and ARC011 Study Groups:. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. *Ann Allergy Asthma Immunol.* 2022 Dec;129(6):758-768.e4. doi: 10.1016/j.anai.2022.07.033. Epub 2022 Aug 13. PMID: 35973655 Clinical Trial
10. Ramsey A, Wu AC, Bender BG, Portnoy J. Teleallergy: Where Have We Been and Where Are We Going? *J Allergy Clin Immunol Pract.* 2022. doi:10.1016/j.jaip.2022.08.032.
11. Ramsey A, Mustafa SS, Portnoy JM. Patient and Clinician Attitudes Toward Telemedicine for Allergy and Immunology. *J Allergy Clin Immunol Pract.* 2022;10(10):2493-9. doi:10.1016/j.jaip.2022.05.008.
12. Pandya A, Waller M, Portnoy JM. The Regulatory Environment of Telemedicine After COVID-19. *J Allergy Clin Immunol Pract.* 2022;10(10):2500-5. doi:10.1016/j.jaip.2022.07.001.
13. Stout S, Murphy H, Pandya A, Yeh HW, Portnoy J. The effect of coronavirus disease 2019 on asthma visits. *Ann Allergy Asthma Immunol.* 2022
14. Portnoy J, Ciaccio C, Beausoleil J, Du Toit G, Fineman S, Tilles S, et al. Eight tips for the implementation of the first licensed peanut allergy oral immunotherapy into clinical practice. *Allergy, Asthma & Clinical Immunology.* 2022. DOI: 10.1186/s13223-022-00671-5
15. Parashar S, Pandya A, Portnoy J. Subcutaneous Allergen Immunotherapy in Pediatrics. *Allergy Asthma Proc.* 2022;43. 10.1186/s13223-022-00671-5
16. Abrams EM, Chan ES, Portnoy J. Evolving Interpretation of Screening and Diagnostic Tests in Allergy. *J Allergy Clin Immunol Pract.* 2021;9(12):4183-91.
17. Persaud YK, Portnoy JM. Ten Rules for Implementation of a Telemedicine Program to Care for Patients with Asthma. *J Allergy Clin Immunol Pract.* 2021;9(1):13-21.
18. Mosnaim G, Safioti G, Brown R, DePietro M, Szeffler SJ, Lang DM, et al. Digital Health Technology in Asthma: A Comprehensive Scoping Review. *J Allergy Clin Immunol Pract.* 2021.
19. Nguyen M, Waller M, Pandya A, Portnoy J. A Review of Patient and Provider Satisfaction with Telemedicine. *Curr Allergy Asthma Rep.* 2020;20(11):72.
20. UG N, Shroba J, Pandya A, Portnoy J. Diagnosis of peanut allergy using continuous likelihood ratios. *Ann Allergy Asthma Immunol.* 2020.
21. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, et al. COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic. *J Allergy Clin Immunol Pract.* 2020.
22. Searing DA, Dutmer CM, Fleischer DM, Shaker MS, Oppenheimer J, Grayson MH, et al. A Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services. *J Allergy Clin Immunol Pract.* 2020;8(7):2125-34.
23. Greenhawt M, Shaker M, Wang J, Oppenheimer JJ, Sicherer S, Keet C, et al. Peanut Allergy Diagnosis- a 2020 Practice Parameter Update, Systematic Review, and GRADE Analysis. *J Allergy Clin Immunol.* 2020; 146(6), 1302-34.
24. Van Mason J, Portnoy JM. Immunologic Strategies for Prevention of Asthma. *Allergy Asthma Proc.* 2020;8:834-47.
25. Waller MR, Taylor LM, Portnoy JM. Benefits and risks of incorporating virtual visits into an allergy/immunology practice. *Allergy Asthma Proc.* 2020;41(2):76-81.
26. Shaker MS, Wallace DV, Golden DB, Oppenheimer J, Bernstein JA, Campbell RC, et al. Anaphylaxis - a 2020 Practice Parameter Update, Systematic Review and GRADE Analysis. *J Allergy Clin Immunol.* 2020.
27. Portnoy JM, Pandya A, Waller M, Elliott T. Telemedicine and emerging technologies for health care in allergy/immunology. *J Allergy Clin Immunol.* 2020;145(2):445-54.

28. August KJ, Farooki S, Fulbright JM, August A, Portnoy JM, Pommert L, et al. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. *Pediatr Blood Cancer*. 2020;67(1):e28021.
29. Waller M, Taylor L, Portnoy J. The Medical Virtualist: Is Pediatric Patient Care Using Telemedicine, a New Specialty? *Pediatr Ann*. 2019;48(6):e243-e8.
30. Taylor L, Waller M, Portnoy JM. Telemedicine for Allergy Services to Rural Communities. *J Allergy Clin Immunol Pract*. 2019.
31. Taylor L, Portnoy JM. Telemedicine for General Pediatrics. *Pediatr Ann*. 2019;48(12):e479-e84.
32. Van Mason J, Portnoy JM. Accelerated Immunotherapy: Why Are We Going So Slow. *Curr Treat Options Allergy*. 2019; 6(4) 396-409. DOI 10.1007/s40521-019-00212-3
33. Poole JA, Barnes CS, Demain JG, Bernstein JA, Padukudru MA, Sheehan WJ, et al. Impact of weather and climate change with indoor and outdoor air quality in asthma: A Work Group Report of the AAAAI Environmental Exposure and Respiratory Health Committee. *The Journal of allergy and clinical immunology*. 2019;143(5):1702-10.
34. Portnoy J, Wade RL, Kessler C. Patient Carrying Time, Confidence, and Training with Epinephrine Autoinjectors: The RACE Survey. *The journal of allergy and clinical immunology In practice*. 2019.
35. Nalin U, Stout S, Portnoy JM. Single inhaler maintenance and reliever therapy in pediatric asthma. *Current opinion in allergy and clinical immunology*. 2019;19(2):111-7.
36. Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, et al. AR101 Oral Immunotherapy for Peanut Allergy. *N Engl J Med*. 2018;379(21):1991-2001.
37. Taylor L, Capling H, Portnoy JM. Administering a Telemedicine Program. *Curr Allergy Asthma Rep*. 2018;18(11):57. doi:10.1007/s11882-018-0812-8.
38. Shih J, Portnoy J. Tips for Seeing Patients via Telemedicine. *Curr Allergy Asthma Rep*. 2018;18(10):50. doi:10.1007/s11882-018-0807-5.
39. Geller-Bernstein C, Portnoy JM. The Clinical Utility of Pollen Counts. *Clin Rev Allergy Immunol*. 2018. doi:10.1007/s12016-018-8698-8.
40. Kader R, Kennedy K, Portnoy JM. Indoor Environmental Interventions and their Effect on Asthma Outcomes. *Curr Allergy Asthma Rep*. 2018;18(3):17.
41. Wallace DV, Dykewicz MS, Oppenheimer J, Portnoy JM, Lang DM. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters. *Annals of internal medicine*. 2017;167(12):876-81.
42. Lang DM, Portnoy JM. Allergy and immunology practice parameters and guidelines: The new normal. *Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology*. 2017;119(6):471-3.
43. Elliott T, Shih J, Dinakar C, Portnoy J, Fineman S. American College of Allergy, Asthma & Immunology Position Paper on the Use of Telemedicine for Allergists. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2017;119(6):512-7.
44. Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, Finegold I, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2017;119(6):489-511 e41.
45. Greenhawt M, Oppenheimer J, Nelson M, et al. Sublingual immunotherapy: A focused allergen immunotherapy practice parameter update. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2017;118(3):276-82 e2.
46. Jara D, Portnoy J, Dhar M, Barnes C. Relation of indoor and outdoor airborne fungal spore levels in the Kansas City metropolitan area. *Allergy and asthma proceedings*. 2017;38(2):130-5.
47. Rudert A, Portnoy J. Mold allergy: is it real and what do we do about it? *Expert review of clinical immunology*. 2017:1-13.
48. Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: A practice parameter update 2016. *Ann Allergy Asthma Immunol*. 2017;118(1):28-54.
49. Allenbrand R, Barnes CS, Mohammed M, et al. Comparison of allergens collected from furnace filters and vacuum floor dust. *Ann Allergy Asthma Immunol*. 2017;118(1):108-9.
50. Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update-2016. *The Journal of allergy and clinical immunology*. 2016.
51. Portnoy JM, Waller M, De Lurgio S, Dinakar C. Telemedicine is as effective as in-person visits for patients with asthma. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2016;117(3):241-5.
52. Portnoy JM, Williams PB, Barnes CS. Innate Immune Responses to Fungal Allergens. *Current allergy and asthma reports*. 2016;16(9):62.
53. Dinakar C, Shroba J, Portnoy JM. The transforming power of proximity food challenges. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2016;117(2):135-7.
54. Baxi SN, Portnoy JM, Larenas-Linnemann D, Phipatanakul W, Environmental Allergens W. Exposure and Health Effects of Fungi on Humans. *The journal of allergy and clinical immunology In practice*. 2016;4(3):396-404.
55. Larenas-Linnemann D, Baxi S, Phipatanakul W, Portnoy JM, Environmental Allergens W. Clinical Evaluation and Management of Patients with Suspected Fungus Sensitivity. *The journal of allergy and clinical immunology In practice*. 2016;4(3):405-14.
56. Williams PB, Barnes CS, Portnoy JM, Environmental Allergens W. Innate and Adaptive Immune Response to Fungal Products and Allergens. *The journal of allergy and clinical immunology In practice*. 2016;4(3):386-95.

57. Hanson JR, Lee BR, Williams DD, et al. Developing a risk stratification model for predicting future health care use in asthmatic children. *Annals of allergy, asthma & immunology*. 2016;116(1):26-30.
58. Shroba J, Hanson J, Portnoy J. Current treatment options for idiopathic angioedema. *Ann Allergy Asthma Immunol*. 2015 Nov;115(5):429-33. PubMed PMID: 26341649.
59. Portnoy JM, Jara D. Mold allergy revisited. *Ann Allergy Asthma Immunol*. 2015 Feb;114(2):83-9. PubMed PMID: 25624128.
60. Portnoy J, Waller M, Dinakar C. TeleAllergy: a new way to manage asthma. *The journal of allergy and clinical immunology In practice*. 2015 Mar-Apr;3(2):302-3. PubMed PMID: 25754720.
61. Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, et al. Anaphylaxis-a practice parameter update 2015. *Ann Allergy Asthma Immunol*. 2015 Nov;115(5):341-84. PubMed PMID: 26505932.
62. Fonacier L, Bernstein DI, Pacheco K, Holness DL, Blessing-Moore J, Khan D, et al. Contact dermatitis: a practice parameter-update 2015. *The journal of allergy and clinical immunology In practice*. 2015 May-Jun;3(3 Suppl):S1-39. PubMed PMID: 25965350.
63. D'Amato G, Holgate ST, Pawankar R, Ledford DK, Cecchi L, Al-Ahmad M, et al. Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization. *The World Allergy Organization journal*. 2015;8(1):25. PubMed PMID: 26207160. Pubmed Central PMCID: 4499913.
64. Ciaccio CE, Barnes C, Kennedy K, Chan M, Portnoy J, Rosenwasser L. Home dust microbiota is disordered in homes of low-income asthmatic children. *J Asthma*. 2015 Oct 29;1-8. PubMed PMID: 26512904.
65. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *J Allergy Clin Immunol*. 2015 Nov;136(5):1186-205 e78. PubMed PMID: 26371839.
66. Barnes CS, Allenbrand R, Mohammed M, Gard L, Pacheco F, Kennedy K, et al. Measurement of aeroallergens from furnace filters. *Ann Allergy Asthma Immunol*. 2015 Mar;114(3):221-5. PubMed PMID: 25457862.
67. Campbell RL, Li JT, Nicklas RA, Sadosty AT, Members of the Joint Task F, Practice Parameter. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. *Annals of allergy, asthma & immunology*. 2014;113(6):599-608.
68. Peters AT, Spector S, Hsu J, Hamilos DL, Baroody FM, Chandra RK, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. *Annals of allergy, asthma & immunology*. 2014;113(4):347-85.
69. Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, et al. Food allergy: A practice parameter update-2014. *The Journal of allergy and clinical immunology*. 2014;134(5):1016-25 e43.
70. Portnoy JM, Shroba J. Managing food allergies in schools. *Current allergy and asthma reports*. 2014;14(10):467.
71. Dinakar C, Portnoy JM. Empowering the child and caregiver: yellow zone Asthma Action Plan. *Current allergy and asthma reports*. 2014;14(11):475.
72. Barnes CS, Allenbrand R, Mohammed M, Gard L, Pacheco F, Kennedy K, et al. Measurement of aeroallergens from furnace filters. *Annals of allergy, asthma & immunology*. 2014.
73. Dinakar C, Oppenheimer J, Portnoy J, Bacharier LB, Li J, Kercsmar CM, et al. Management of acute loss of asthma control in the yellow zone: a practice parameter. *Ann Allergy Asthma Immunol*. 2014 Aug;113(2):143-59. PubMed PMID: 25065350.
74. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. *The Journal of allergy and clinical immunology*. 2014; 133 (5):1270-7.
75. Portnoy J, Miller JD, Williams PB, Chew GL, Miller JD, Zaitoun F, et al. Environmental assessment and exposure control of dust mites: a practice parameter. *Annals of allergy, asthma & immunology*. 2013 Dec; 111 (6):465-507.
76. Ciaccio CE, DiDonna AC, Kennedy K, Barnes CS, Portnoy JM, Rosenwasser LJ. Association of tobacco smoke exposure and atopic sensitization. *Annals of allergy, asthma & immunology*. 2013 Nov; 111 (5):387-90.
77. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, LeBovidge J, et al. Atopic dermatitis: a practice parameter update 2012. *J Allergy Clin Immunol*. 2013 Feb; 131 (2):295-9 e1-27.
78. Portnoy J, Chew GL, Phipatanakul W, Williams PB, Grimes C, Kennedy K, et al. Environmental assessment and exposure reduction of cockroaches: A practice parameter. *J Allergy Clin Immunol*. 2013 Oct; 132 (4):802-8 e25.
79. Zuraw BL, Bernstein JA, Lang DM, Craig T, Dreyfus D, Hsieh F, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. *The Journal of allergy and clinical immunology*. 2013 Jun;131(6):1491-3.
80. Hahtela T, Holgate S, Pawankar R, Akdis CA, Benjaponpitak S, Caraballo L, et al. The biodiversity hypothesis and allergic disease: world allergy organization position statement. *The World Allergy Organization journal*. 2013; 6 (1):3.
81. Duncan CL, Hogan MB, Tien KJ, Graves MM, Chorney JM, Zettler MD, et al. Efficacy of a parent-youth teamwork intervention to promote adherence in pediatric asthma. *Journal of pediatric psychology*. 2013 Jul; 38 (6):617-28.
82. Barnes C, Portnoy JM, Ciaccio CE, Pacheco F. A comparison of subject room dust with home vacuum dust for evaluation of dust-borne aeroallergens. *Annals of allergy, asthma & immunology*. 2013 May;110 (5):375-9.
83. Phipatanakul W, Matsui E, Portnoy J, et al. Environmental assessment and exposure reduction of rodents: a practice parameter. *Ann Allergy Asthma Immunol*. 2012; 109(6):375-387.
84. Ciaccio CE, Kennedy K, Portnoy JM. A New Model for Environmental Assessment and Exposure Reduction. *Curr Allergy Asthma Rep*. 2012. Epub 2012/08/31.

- 
85. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. *J Allergy Clin Immunol.* 2012; 130 (1):25-43. Epub 2012/05/23.
  86. Portnoy J, Kennedy K, Sublett J. Environmental assessment and exposure control: a practice parameter--furry animals. *Ann Allergy Asthma Immunol.* 2012; 108 (4):223 e1-15. Epub 2012/04/04.
  87. **Portnoy JM.** Appropriate allergy testing and interpretation. *Mo Med.* 2011 Sep-Oct; 108 (5):339-43.
  88. Ziska L, Knowlton K, Rogers C, Dalan D, Tierney N, Elder MA, et al. Recent warming by latitude associated with increased length of ragweed pollen season in central North America. *Proc Natl Acad Sci U S A.* 2011 Mar 8; 108 (10):4248-51.
  89. Golden DB, Moffitt J, Nicklas RA, Freeman T, Graft DF, Reisman RE, et al. Stinging insect hypersensitivity: A practice parameter update 2011. *J Allergy Clin Immunol.* 2011 Apr; 127 (4):852-4 e23.
  90. Greenhawt MJ, Li JT, Bernstein DI, Blessing-Moore J, Cox L, Khan D, et al. Administering influenza vaccine to egg allergic recipients: a focused practice parameter update. *Ann Allergy Asthma Immunol.* 2011 Jan; 106 (1):11-6.
  91. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. *J Allergy Clin Immunol.* 2011 Jan; 127 (1 Suppl):S1-55.
  92. Weiler JM, Anderson SD, Randolph C, Bonini S, Craig TJ, Pearlman DS, et al. Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. *Ann Allergy Asthma Immunol.* 2010 Dec;105(6 Suppl):S1-47.
  93. Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. *J Allergy Clin Immunol.* 2010 Sep;126(3):477-80 e1-42.
  94. Barnes CS, Amado M, **Portnoy JM.** Reduced clinic, emergency room, and hospital utilization after home environmental assessment and case management. *Allergy Asthma Proc.* 2010. Jul;31(4):317-23.
  95. Williams D, Portnoy JM, Meyerson K. Strategies for improving asthma outcomes: a case-based review of successes and pitfalls. *J Manag Care Pharm.* 2010 Feb;16(1 Suppl C):S3-14; quiz S6-7.
  96. Bernstein JA, Prenner B, Ferguson BJ, **Portnoy J,** Wheeler WJ, Sacks HJ. Double-blind, placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis. *Am J Rhinol Allergy.* 2009 Sep-Oct;23(5):512-7.
  97. Johnson L, Ciaccio C, Barnes CS, Kennedy K, Forrest E, Gard LC, ..., **Portnoy J.** Low-cost interventions improve indoor air quality and children's health. *Allergy Asthma Proc.* 2009 Jul-Aug;30(4):377-85.
  98. Kelso JM, Li JT, Nicklas RA, Blessing-Moore J, Cox L, Lang DM, ..., **Portnoy J,** et al. Adverse reactions to vaccines. *Ann Allergy Asthma Immunol.* 2009 Oct;103(4 Suppl 2):S1-14.
  99. Lupoli TA, Ciaccio, CE, **Portnoy JM.** Home and School Environmental Assessment and Remediation. *Curr Allergy Asthma Rep.* 2009. 9. (6): 419-25.
  100. Ramos C, Ciaccio C, **Portnoy, J.** Asthma control is enhanced when Health Plans and Providers cooperate. *Pediatric Annals.* 2009; 38(3) 135-42.
  101. Nelson HS, Carr W, Nathan R, **Portnoy JM.** Update on the safety of long-acting beta-agonists in combination with inhaled corticosteroids for the treatment of asthma. *Ann Allergy Asthma Immunol.* 2009; 102: 11-15.
  102. Ciaccio C, **Portnoy JM.** Strategies for Primary Prevention of Atopy in Children. . *Curr Allergy Asthma Rep.* 2008. 8. (6): 493-9.
  103. Rodriguez-Perez N, Penagos M, **Portnoy J.** New types of Immunotherapy in Children. *Curr Allergy Asthma Rep.* 2008;8 (6): 484-92.
  104. Wallace D, Dykewicz M, ... **Portnoy JM,** et al. Diagnosis and Management of Rhinitis: An Updated Practice Parameter. *J Allergy Clin Immunol* 122(2 Suppl): S1-84
  105. **Portnoy, J.M.,** C.S. Barnes, and K. Kennedy, Importance of mold allergy in asthma. *Curr Allergy Asthma Rep.* 2008. 8(1): p. 71-8.
  106. Bernstein IL, Blessing-Moore J, Cox L, Lang D, Nicklas R, Oppenheimer J, **Portnoy JM,** et al. Allergy Diagnostic Testing: An Updated Practice Parameter. *Ann Allergy Asthma Immunol.* 2008. 100 (3 Suppl): S1-S148
  107. Barnes, C., Kennedy K, Gard L, ... ,**Portnoy J.,** The impact of home cleaning on quality of life for homes with asthmatic children. *Allergy Asthma Proc,* 2008; 29(2), 197-204.
  108. Graves MM, Adams CD, Bender JA, Simon S, **Portnoy JM.** Volitional Nonadherence in Pediatric Asthma: Parental Report of Motivating Factors. *Current Allergy and Asthma Reports.* 2007; 7: 427-32.
  109. Cox L, Li JT, Nelson H, Lockey R, ..., Oppenheimer J, **Portnoy JM,** Schuller DE, et al, Allergen immunotherapy: a practice parameter second update. *J Allergy Clin Immunol,* 2007. 120(3 Suppl): p. S25-85.
  110. **Portnoy JM.,** Kennedy K, Barnes CS, Controversies regarding dampness and mold growth in homes. *Allergy Asthma Proc,* 2007. **28(3):** p. 257-8.
  111. McNairn, JD., Ramos C, **Portnoy JM,** Outcome measures for asthma disease management. *Curr Opin Allergy Clin Immunol,* 2007. **7(3):** p. 231-5.
  112. Barnes CS, Dowling P, VanOsdol T, **Portnoy J.** Comparison of indoor fungal spore levels before and after professional home remediation. . *Ann Allergy Asthma Immunol.* 2007; 98, 262-8.
  113. Bernstein IL, ... **Portnoy J,** et al. Contact dermatitis: a practice parameter. *Ann Allergy Asthma Immunol,* 2006. **97(3 Suppl 2):** p. S1-38.
  114. **Portnoy JM,** Amado, MC. Evidence-based Allergy Diagnostic Tests. *Current Allergy and Asthma Reports.* 2006; 6: 455-61.
  115. **Portnoy JM,** Jennings D. Utilization patterns in an asthma intervention. *Ann Allergy Asthma Immunol.* 2006 Jul;97(1 Suppl 1):S25-30.
-

- 
116. Chapman J, Bernstein IL, Lee R, Oppenheimer J, Nicklas R, **Portnoy JM**, et al. Food Allergy: A Practice Parameter. *Annals Allergy Asthma Immunol.* 2006; 96(3 suppl 2): S1-S68.
  117. Bush RK, **Portnoy JM**, Saxon A, Terr AI, Wood RA. The medical effects of mold exposure. *J Allergy Clin Immunol.* 2006; 117: 326-33.
  118. Barnes C, **Portnoy J**, Sever M, Arbes S, Jr., Vaughn B, Zeldin DC. Comparison of enzyme immunoassay-based assays for environmental *Alternaria alternata*. *Ann Allergy Asthma Immunol.* 2006 Sep;97(3):350-6.
  119. Amado MC, **Portnoy JM**. Diagnosing asthma in young children. *Current Opinion in Allergy & Clinical Immunol.* 2006; 6 (2):101-105.
  120. Graves MM, Adams CD, **Portnoy J**. Adherence in young children with asthma. *Current Opinion in Allergy & Clinical Immunology* 2006; 6 (2):124-127.
  121. Chapman J, Bernstein I, Lee R, Oppenheimer J, Nicklas R, **Portnoy J**, et al. Food allergy: a practice parameter. *Ann Allergy Asthma Immunol.* 2006 Mar;96(3 Suppl 2):S1-68.
  122. Amado M, **Portnoy J**. Recent Advances in Asthma Management. *Missouri Medicine* 2006;103(1):58-61.
  123. Li J, Oppenheimer J, Bernstein IL, Nicklas R, Khan D, Blessing-Moore J, Lang D, **Portnoy J**, Schuller D, Spector S, Tilles S, Wallace D. Attaining optimal asthma control: A practice parameter. *J Allergy Clin Immunol.* 2005; 116 (5 suppl), S3-S11.
  124. Lieberman P, Bernstein IL, Nicklas R, ... **Portnoy J**, et al. Practice Parameter for the Diagnosis and Management of Anaphylaxis. *J Allergy Clin Immunol.* 2005; 115(3,suppl).
  125. Slavin RG, Spector SL, Bernstein IL, ... **Portnoy J**, et al. The diagnosis and management of sinusitis: a practice parameter update. *J Allergy Clin Immunol* 2005;116(6 Suppl):S13-47.
  126. Bonilla A, Bernstein IL, Nicklas R, ... **Portnoy J**, et al. Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency. *Ann Allergy Asthma Immunol.* 2005; 94(5 suppl 1).
  127. **Portnoy JM**, Kennedy K, Barnes C. Sampling for indoor fungi: what the clinician needs to know. *Curr Opin Otolaryngol Head Neck Surg* 2005;13(3):165-170.
  128. **Portnoy J**, Kwak K, VanOsdol T, Dowling P, Barnes C. Health Effects of Indoor Fungi. *Ann Allergy Asthma Immunol.* 2005; 94(3): 313-9.
  129. **Portnoy J**, Barnes CS. The National Allergy Bureau: pollen and spore reporting today. *J Allergy Clin Immunol* 2004;114(5):1235-8.
  130. **Portnoy J**, VanOsdol T, Williams PB. Evidence-Based Strategies for Treatment of Allergic Rhinitis. *Current Allergy and Asthma Reports.* 2004 ; 4 : 439-46.
  131. Adams C, Dryer M, Dinakar, C, **Portnoy, J**. Pediatric Asthma: A look at adherence from the patient and family perspective. *Current Allergy and Asthma Reports.* 2004 ; 4 : 425-32.
  132. Leung DYM, Nicklas R, Li J, Bernstein IL, Blessing-Moore J, Boguniewicz M, Chapman J, Khan D, Lang D, Lee R, **Portnoy JM**, Schuller D, Spector S, Tilles S. Disease Management of Atopic Dermatitis: An Updated Practice Parameter. *Ann Allergy Asthma Immunol.* 2004; 93 (3 suppl 2): S1-S21.
  133. **Portnoy J**, Dinakar C. Review of cetirizine hydrochloride for the treatment of allergic disorders. *Expert Opin Pharmacother.* 2004; 5(1): 125-35.
  134. **Portnoy JM**, Barnes CS, Kennedy K. Sampling for indoor fungi. *J Allergy Clin Immunol* 2004;113(2):189-98; quiz 199
  135. Dinakar C, **Portnoy JM**. Allergen immunotherapy in the prevention of asthma. *Curr Opin Allergy Clin Immunol.* 2004; 4(2): 131-136.
  136. Miller K, Ward-Smith P, Cox K, Jones EM, **Portnoy J**. Development of an asthma disease management program in a Children's hospital. *Current Allergy and Asthma Reports.* 2003; 3(6), 491-500.
  137. Jones EM, **Portnoy J**. Modification of provider behavior to achieve improved asthma outcomes. *Current Allergy and Asthma Reports.* 2003; 3(6), 484-90.
  138. **Portnoy J**, Barnes C. Clinical relevance of spore and pollen counts. *Immunol Allergy Clin N. America.* 2003; 23(3):389-410.
  139. Williams PB, Ahlstedt S, Barnes JH, Soderstrom L, **Portnoy J**. Are our impressions of allergy test performances correct? *Ann Allergy Asthma Immunol* 2003;91(1):26-33.
  140. Spector SL, Nicklas RA, Chapman JA, Bernstein IL, Berger WE, Blessing-Moore J, Dykewicz M. S., Fineman S. M, Lee R. E., Li J. T, **Portnoy J. M.**, Schuller D. E., Lang D.Tilles, S. A.. Symptom severity assessment of allergic rhinitis: part 1. *Ann Allergy Asthma Immunol* 2003;91(2):105-14.
  141. Simons FE, Silas P, **Portnoy JM**, Catuogno J, Chapman D, Olufade AO, et al. Safety of cetirizine in infants 6 to 11 months of age: a randomized, double-blind, placebo-controlled study. *J Allergy Clin Immunol* 2003;111(6):1244-8
  142. **Portnoy J**, Jones E. Pediatric asthma emergencies. *J Asthma* 2003;40 Suppl:37-45
  143. Li J, Lockey R, Bernstein I, **Portnoy J**, Nicklas R. Allergen immunotherapy: a practice parameter. *Ann Allergy* 2003;90(1)
  144. **Portnoy JM**, Jones EM. Diagnosing asthma in young children. *Current Allergy and Asthma Reports.* 2002; 2(6), 447-52.
  145. Barnes CS, Pacheco F, Buckley S, **Portnoy JM**. IgE Reactive Proteins from *Stachybotrys chartarum*. *Annals of Allergy Asthma and Immunology.* 2002; 89(1): 29-33.
  146. Barnes CS, Pacheco F, Landuyt J, Hu F, **Portnoy JM**. The effect of temperature, relative humidity and rainfall on airborne ragweed pollen concentrations. *Aerobiologia.* 2001; 17: 61-8.
  147. Esch R, **Portnoy JM**. Allergen Immunotherapy. *Current Allergy and Asthma Reports.* 2001; 1(6), 491-7.
  148. **Portnoy JM**. Immunotherapy for allergic diseases. *Clin Rev Allergy Immunol:*2001;21(2-3):241-259.
-



- 
149. Graft DF, Bernstein DI, Goldsobel A, Meltzer EO, **Portnoy JM**, Long J. Safety of fexofenadine in children treated for seasonal allergic rhinitis. *Ann Allergy Asthma Immunol*. 2001;87(1):22-26.
  150. **Portnoy JM**. Immunotherapy for asthma: Unfavorable studies. *Ann Allergy*. 2001; 87(Suppl), 28-32.
  151. Barnes CS, Tuck J, Simon S, Pacheco F, Hu F, **Portnoy JM**. Allergenic materials in the house dust of allergy clinic patients. *Ann Allergy*. 2001; 86; 517-23.
  152. **Portnoy JM**. Immunotherapy for inhalant allergies. *Postgraduate Medicine*. 2001; 109(5); 89-106.
  153. **Portnoy JM**, Flappan S, Barnes CS. A procedure for evaluation of the indoor environment. *Aerobiologia*. 2001; 17; 43-48.
  154. Williams PB, Siegel C, **Portnoy JM**. Efficacy of a single diagnostic test for sensitization to common inhalant allergens. *Ann Allergy*. 2001 86; 196-202.
  155. Barnes CS, Pacheco F, Landuyt J, Hu F, **Portnoy JM**. Hourly Variation Of Airborne Ragweed Pollen In Kansas City. *Ann Allergy*. 2001; 86; 166-71.
  156. Bush R, **Portnoy JM**. The role and abatement of fungal allergens in allergic disease. *J Allergy Clin Immunol*. 2001; 107: S430-40.
  157. Williams PB, Siegel C, **Portnoy JM**. UniCAP Phadiotop- An accurate test for sensitization to common inhalant allergens. *Allergy*. 2000; 55:269-70.
  158. Barnes C, Schreiber K, Pacheco F, Landuyt J, Hu F, and **Portnoy JM**. Comparison of outdoor allergenic particles and allergen levels. *Annals of Allergy, Asthma and Immunology*. 2000; 84; 47-54.3
  159. **Portnoy JM**, Landuyt J, Pacheco F, Simon S, and Barnes C. A Comparison of the Burkard and Allergenco MK-3 Volumetric Collectors. *Annals of Allergy, Asthma and Immunology*. 2000; 84: 19-24.
  160. Flappan S, **Portnoy JM**, Jones P, Barnes C. Infant Pulmonary Hemorrhage in a Suburban Home with Water Damage and Stachybotrys. *Environ Health Perspect* 1999; 107 (11): 927.
  161. Miller C, Flappan S, **Portnoy JM**. Improved Asthma Control after Remediation of Environmental Stachybotrys Contamination. *Resp Reviews*. 1999; 4(3), 30-2.
  162. Bernstein IL, Gruchalla R, Lee R, Nicklas R, Dykewicz M, et al. Disease Management of Drug Hypersensitivity: A Practice Parameter. *Annals of Allergy, Asthma, and Immunology*. 1999; 83 (6), 665-700.
  163. **Portnoy JM**, Moffitt J, Golden D, Bernstein IL, et al. Stinging Insect Hypersensitivity: A Practice Parameter. *J Allergy Clin Immunol*. 1999; 103(5); 963-80.
  164. **Portnoy JM**, Brothers D, Pacheco F, Landuyt J, Barnes C. Monoclonal antibody-based assay for Alt a1, a major *Alternaria* allergen. *Ann Allergy Asthma Immunol* 1998;81(1):59-64.
  165. Rosenthal D, Hu F, Pacheco F, Landuyt J, Barnes C, **Portnoy JM**. Northern blot identification of mRNA containing sequence for protein allergen, Alt a1, in eight strains of *Alternaria alternata*. *Ann Allergy Asthma Immunol* 1998;80(6):471-5.
  166. Li J, Pearlman D, Nicklas R, Lowenthal M, Rosenthal R, Bernstein IL, Berger W, Kykewicz M, Fineman S, Lee R, **Portnoy JM**, Spector S. Algorithm for the diagnosis and management of asthma: a practice parameter update. *Ann Allergy*. 1998; 81 (5pt1),415-20.
  167. **Portnoy JM**, Finegold I. Ragweed immunotherapy in adult asthma [letter; comment]. *N Engl J Med* 1996;335(3):203-4; discussion 205-6.
  168. Barnes CS, Pacheco F, Landuyt J, Rosenthal D, Hu F, **Portnoy JM**. Production of a recombinant protein from *Alternaria* containing the reported N-terminal of the Alt a1 allergen. *Adv Exp Med Biol* 1996;409:197-203.
  169. Cage BR, Schreiber K, Barnes C, **Portnoy JM**. Evaluation of four bioaerosol samplers in the outdoor environment. *Ann Allergy Asthma Immunol* 1996;77(5):401-6.
  170. Sharkey P, **Portnoy JM**. Rush immunotherapy: experience with a one-day schedule [see comments]. *Ann Allergy Asthma Immunol* 1996;76(2):175-80.
  171. Friesen CA, Wiens LA, Burry VF, **Portnoy JM**, Roberts CC. C-Reactive protein in acute pulmonary exacerbations of patients with cystic fibrosis. *Pediatric Pulmonology*. 1995; 20, 215-9.
  172. **Portnoy JM**, King K, Kanarek H. Premedication reduces the incidence of systemic reactions during rush immunotherapy. *Ann Allergy*. 1994; 73(5) , 409-18.
  173. **Portnoy JM**, Pacheco F, Upadrashta B, Barnes C. A double monoclonal antibody assay for the *Alternaria* allergen GP70. *Annals of Allergy* 1993;71(4):401-7.
  174. Chippis B, Sullivan W, **Portnoy JM**. Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. *Pediatr Infect Dis J*. 1993; 12(8), 653-8.
  175. Barnes C, Upadrashta B, Pacheco F, **Portnoy JM**. Enhanced sensitivity of immunoblotting with peroxidase conjugated antibodies using an immobilized substrate method. *J Chromatography*. 1993; 613(2),281-8.
  176. **Portnoy JM**, Pacheco F, Barnes C, Upadrashta B, Crenshaw R, Esch R. Selection of representative *Alternaria* strain groups based on morphology, enzyme profile, and allergen content. *J Allergy Clin Immunol*. 1993;91(3),773-82.
  177. **Portnoy JM**, Pacheco F, Ballam Y, Barnes C. The effect of time and extraction buffers on residual protein and allergen content of extracts derived from four strains of *Alternaria*. *J Allergy Clin Immunol*. 1993; 91(4),930-8.
  178. Wiens L, Sabath R, Ewing L, Gowdmarajan R, **Portnoy JM**, Scagliotti D. Chest pain in children and adolescents is frequently caused by exercise-induced asthma. *Pediatrics*. 1992;90(3):350-3.
  179. **Portnoy JM**, Nadel G, Amado M, Willsie-Ediger S. A Review of Continuous Nebulization of Beta Agonists in Status Asthmaticus. *Ann Allergy*. 1992;69(1):71-9.
-

180. **Portnoy JM**, King K, Kanarek H, Horner S. Incidence of systemic reactions during rush immunotherapy. *Ann Allergy*. 1992;**68**(6):493-8.
181. Guss S, **Portnoy JM**. Methotrexate treatment of severe asthma in children. *Pediatrics*. 1992;**89**(4):635-9.
182. **Portnoy JM**. Diagnosis of Allergic Diseases. *Children's Hospital Quarterly*. 1991; 2(2),181-4.
183. **Portnoy JM**. Management of Allergic Rhinitis. *Children's Hospital Quarterly*. 1991; 2(2),185-9.
184. Horner S, Guss S, **Portnoy JM**. Immunodeficiency Associated with a Complete Lack of CD8 Cells. *Immunol & Allergy Prac*. 1991;13(2),17-21.
185. **Portnoy JM**, Pacheco F, Ballam Y, Barnes C. Separation of *Alternaria* into Protein and Carbohydrate Fractions Using Phenylsepharose. *J Allergy Clin Immunol*. 1991;87,789-93.
186. Estrada V, **Portnoy JM**. Diabetes Insipidus Exacerbated by Allergic Rhinitis. *Immunol & Allergy Prac*. 1990;12,13-6.
187. **Portnoy JM**, Olson I, Pacheco F, Barnes C. Affinity Purification of a Major *Alternaria* Allergen Using a Monoclonal Antibody. *Ann Allergy*. 1990; 65,109-14.
188. Estrada V, King K, **Portnoy JM**. The use of home nebulizers for the prevention of asthma-related morbidity. *Ped Asthma, Allergy, Immunol*. 1989; 3(4); 227-31.
189. Gill F, **Portnoy JM**. An unusual combination of immunologic abnormalities in a patient with Chronic Mucocutaneous Candidiasis. *Ann Allergy*. 1989;63, 98.
190. **Portnoy JM**, Hicks R, Pacheco F, Olson L. A pilot study of recombinant interferon-alpha for treatment of infants with Respiratory Syncytial Virus-induced bronchiolitis. *Antimicrobial Agents and Chemotherapy*. 1988;32,589
191. **Portnoy JM**, Aggarwal J. Continuous terbutaline nebulization for the treatment of severe exacerbations of asthma in children. *Ann Allergy*. 1988;60,368.
192. **Portnoy JM**, Chapman J, Burge H, Muilenberg M, Solomon W. Epicoccum allergy: skin reaction patterns and spore/mycelium disparities recognized by IgG and IgE ELISA inhibition. *Annals of Allergy*. 1987;59,39.
193. Fitzmaurice L, **Portnoy JM**. A Patient With Functional Humoral Immunodeficiency and Normal Quantitative Immunoglobulins. *Immunology and Allergy Practice*. *Immunology & Allergy Practice*. 1987; 9, 220.
194. Aggarwal J, **Portnoy JM**. Intractable sneezing with a specific psychogenic origin. *Annals of Allergy*, 1986;56,345.
195. **Portnoy JM**, Olson L. Normal cerebrospinal fluid values in children: Another look. *Pediatrics*. 1985;75,484-87
196. Sarnat HB, **Portnoy JM**, Chi DY. Effects of denervation and tenotomy on the gastrocnemius muscle in the frog: a histologic and histochemical study. *Anat Rec*. 1977;187(3):335-46.

### Editorials:

1. Portnoy JM, Oppenheimer JJ. Can an Artificial Intelligence (AI) Be an Author on a Medical Paper? *J Allergy Clin Immunol Pract*. 2023 Jul;11(7):2067-2068. doi: 10.1016/j.jaip.2023.04.034. Epub 2023 May 2. PMID: 37142162
2. Pandya A, Portnoy J. Does improved indoor air quality lead to better asthma control? *Ann Allergy Immunol*. 2023 Feb; 130(2); 147-48.
3. Rehman N, Portnoy J, Wu AC. Could Telemedicine Be Here to Stay? Understanding the Rapidly Changing Landscape of Telemedicine in Allergy and Immunology Practice. *J Allergy Clin Immunol Pract*. 2022;10(10):2550-1. doi:10.1016/j.jaip.2022.08.012.
4. Parashar S, Portnoy J. Is More Documentation Better for Adverse Drug Reactions? *J Allergy Clin Immunol Pract*. 2022;10(10):2772-3. doi:10.1016/j.jaip.2022.07.023.
5. Lang DM, Portnoy JM, Oppenheimer JJ. Just Listen to Your Patient. *J Allergy Clin Immunol*. 2020.
6. Makhija M, Waller M, Portnoy JM. Telemedicine in School for Asthma Education. *J Allergy Clin Immunol Pract*. 2020;8 (in press).
7. Wu AC, Rehman N, Portnoy J. The Good, the Bad, and the Unknown of Telemedicine in Asthma and Allergy Practice. *J Allergy Clin Immunol Pract*. 2019;7(8):2580-2.
8. Portnoy JM, Brush AC, Honsinger RW. e-Consults in Allergy and Immunology: "Why Am I Here?". *J Allergy Clin Immunol Pract*. 2019;7(8):2603-5.
9. Portnoy J, Miller C. Relationship between exposure to fungi and asthma-an ongoing conundrum. *Ann Allergy Asthma Immunol*. 2019;122(6):554-5.
10. Portnoy JM, Waller M, Farrell K. Telemedicine Improves Allergy Care for Hospitalized Patients. *J Allergy Clin Immunol Pract*. 2018;6(6):2041-2. doi:10.1016/j.jaip.2018.05.016.
11. Portnoy JM, Wu AC. Is Telemedicine as Effective as Usual Care? *J Allergy Clin Immunol Pract*. 2019;7(1):217-8. doi:10.1016/j.jaip.2018.09.002.
12. Portnoy, J. M. and T. Elliott (2019). "Tele-Allergy: Here Today and Rapidly Advancing." *J Allergy Clin Immunol Pract* 7(3): 1022-1023.
13. Portnoy JM, Waller M, Farrell K. Telemedicine Improves Allergy Care for Hospitalized Patients. *J Allergy Clin Immunol Pract*. 2018;6(6):2041-2. doi:10.1016/j.jaip.2018.05.016.
14. Portnoy JM, Murphy H. Is it time for asthma action plan apps? *Annals of allergy, asthma & immunology* : official publication of the American College of Allergy, Asthma, & Immunology. 2017;118(3):239-40.
15. Portnoy JM and Cox LS. Is the benefit from prescribing epinephrine autoinjectors for sublingual immunotherapy worth the cost? Lessons learned from clinical trials. *The journal of allergy and clinical immunology In practice*. 2017;6(1):90-1.
16. Dinakar, C. and **J. Portnoy** (2014). "Sailing to the port of best practice on the A/I practice parameters Mayflower." *Ann Allergy Asthma Immunol* 113(2): 123-124.
17. **Portnoy JM**. It's about time for allergenic extracts to undergo review. *Ann Allergy Asthma Immunol*. 2012;109(1):3-4. Epub 2012/06/26.

18. Ciaccio CE, **Portnoy JM**. Spacers and Valved Holding Chambers in Asthma Drug Delivery: How Many Breaths Are Needed to Achieve Adequate Lung Deposition? *Curr Allergy Asthma Rep*. 2011 Sep 8.
19. **Portnoy JM**. Skin testing. *Curr Allergy Asthma Rep*. 2006 Nov;6(6):453-4.
20. **Portnoy JM**. Usual pharmacotherapy for asthma. *Curr Allergy Asthma Rep*. 2006 Nov;6(6):453.
21. **Portnoy JM**. Asthma control test. *Curr Allergy Asthma Rep*. 2006 Nov;6(6):454.
22. **Portnoy JM**. Diagnostic testing for allergies. *Ann Allergy Asthma Immunol* 2006;96(1):3-4.
  
23. **Portnoy JM**. Barriers to asthma treatment adherence. *Curr Allergy Asthma Rep* 2005;5(6):430.
24. **Portnoy JM**. Corticosteroids for mild persistent asthma. *Curr Allergy Asthma Rep* 2005;5(6):429.
25. **Portnoy JM**. Nitric oxide measurements in chronic asthma. *Curr Allergy Asthma Rep* 2005;5(6):429-30.
26. **Portnoy JM**. Rhinitis therapy in preventing hospitalization for asthma. *Curr Allergy Asthma Rep* 2004 Nov;4(6):424.
27. **Portnoy JM**. Exhaled Nitric Oxide versus conventional tests for asthma. *Curr Allergy Asthma Rep* 2004 Nov;4(6):423.
28. **Portnoy JM**. Strategies for evaluating allergic rhinitis. *Curr Allergy Asthma Rep* 2004 Nov;4(6):423.
29. **Portnoy JM**. In my opinion – Interview with the Expert. *Pediatric Asthma Allergy & Immunol*. 2004; 17(2), 156-60.
30. **Portnoy JM**. What do Pollen Counts Mean? *Ann Allergy Asthma Immunol*. 2004; 93(2), 109-10.
31. **Portnoy JM**, Improving childhood asthma outcomes in the United States. *Curr Allergy Asthma Rep* 2003 Nov;3(6):466
32. **Portnoy JM**, Pediatric asthma management programs. *Curr Allergy Asthma Rep* 2003 Nov;3(6):465
33. **Portnoy JM**, Daily controller medicine in children with mild persistent asthma. *Curr Allergy Asthma Rep* 2003 Nov;3(6):465
34. **Portnoy JM**, Simon SD. Is 3-mm less drowsiness important? *Ann Allergy Asthma Immunol*. 2003; 91(4):324-25.
35. **Portnoy JM**. Outcomes to measure the effectiveness of asthma treatment. *Ann Allergy Asthma Immunol*. 2003; 91(3):220-21.
36. **Portnoy JM**. Evaluation of indoor mold exposure is what allergists do best. *Ann Allergy Asthma Immunol* 2003;90(2):175.
37. **Portnoy JM**, What do allergy skin tests really mean? *Annals of Allergy Asthma and Immunology*. 2002; 89(4): 335-6.
38. **Portnoy JM**, Relationship of adherence to pediatric asthma morbidity among inner-city children. *Curr Allergy Asthma Rep* 2002 Nov;2(6):445-6
39. **Portnoy JM**, A qualitative study of action plans for asthma. *Curr Allergy Asthma Rep* 2002 Nov;2(6):445

#### Book Chapters:

1. Portnoy J, Pandya A. Drug Allergy. In: Vedanthan P, Nelson H, Agashe S, Mahesh P, Katial R, editors. *Textbook of Allergy for the Clinician*. 2nd ed. Boca Raton, FL: CRC Press; 2021. p. 387-402.
2. Mendell MJ, Portnoy J, Miller JD (2019) Indoor mold: Basis for health concerns. In: Hung LL, Caufield, S, Miller JD (eds) *Recognition, Evaluation and Control of Indoor Mold*. American Industrial Hygiene Association, Fairfax, VA. p.3-13.
3. Portnoy J, Partridge M. Health Care Delivery and Health Economics in Allergy. In: Powankar R, Canonica GW, Holgate S, Lockey R, editors. *WAO White Book on Allergy: World Allergy Organization Education, Council*; 2011. p. 139-41.
4. Portnoy, J. and M. Amado (2009). The Costs of Allergy and Asthma and the Potential Benefit of Prevention Strategies. *Allergy Frontiers: Diagnosis and Health Economics*. R. Pawankar, Springer. 4: 491-506.
5. Fischer T, Gruchalla R. Allergy and Immunology Medical Knowledge Self-Assessment Program (MKSAP). *Chapters on Insect Sensitivity, Asthma, and Immunotherapy*. 2003.
6. Mathews K. **Portnoy JM**, Allergic Rhinitis. in: *Current Therapy in Allergy. Immunology and Rheumatology*. Lichtenstein & Fauci eds. B C Decker Inc-Publisher. 1984.

#### Letters to Editor:

1. Portnoy J, Abrams EM, Chan ES. Reply to "The added value of reporting likelihood ratios to laboratory test results in allergy and clinical immunology". *J Allergy Clin Immunol Pract*. 2022;10(6):1668. doi:10.1016/j.jaip.2022.02.042
2. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, et al. Reply to "Subcutaneous terbutaline as an alternative to aerosolized albuterol". *J Allergy Clin Immunol Pract*. 2020;8(7):2450-2.
3. Portnoy JM. Author's response. *Ann Allergy Asthma Immunol*. 2015 Jun;114(6):539-40. PubMed PMID: 26021900.
4. Williams PB, Portnoy J. Comparing specific IgE values of 2 different assays. *Ann Allergy Asthma Immunol*. [Letter]. 2011 Dec;107(6):550.
5. Spector S, Wallace D, Nicklas R, Portnoy J, Blessing-Moore J, Bernstein D, et al. Comments on Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines. *J Allergy Clin Immunol*. 2011 Jun;127(6):1641-2; author reply 3-5.
6. Portnoy JM, Sampson H. Management of allergic rhinitis. *Lancet*. 2008 Sep 20;372(9643):1037.